about
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.Intertumoral Heterogeneity within Medulloblastoma Subgroups.An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.To the nucleolar density and size in apoptotic human leukemic myeloblasts produced in vitro by Trichostatin A.Experimental therapy with 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP): origin of resistance.Effect of histone deacetylase inhibitors on the cell nucleus and nucleolus of leukemic myeloblasts in vitro - a cytochemical study.The effect of a histone deacetylase inhibitor - valproic acid - on nucleoli in human leukaemic myeloblasts.AT-19SYSTEMATIC RADIOLOGICAL PHENOTYPING OF ATYPICAL TERATOID RHABDOID TUMOURS USING LANGUAGE MODELLED MACHINE LEARNING APPROACHES.PNR-33MOLECULAR RE-EVALUATION OF INSTITUTIONALLY DIAGNOSED CNS-PNETS: CLINICAL CONSEQUENCES OF CONFINED DIAGNOSTIC GROUPS.HG-57RE-IRRADIATION IN PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMAS, AN UPDATE ON THE CANADIAN EXPERIENCE.LG-46INFERIOR OUTCOME AND POOR RESPONSE TO CONVENTIONAL THERAPIES IN PEDIATRIC LOW-GRADE GLIOMAS HARBORING THE BRAF V600E MUTATION.LG-52THEOPHYLLINE IN VISION IMPAIRED CHILDREN WITH OPTIC PATHWAY GLIOMA.LG-58THERAPEUTIC IMPLICATIONS OF MOLECULAR BIOMARKERS IN INFANTS WITH PEDIATRIC LOW-GRADE GLIOMA.LG-68THE GENETIC AND CLINICAL LANDSCAPE IN PEDIATRIC LOW GRADE GLIOMA; PRELIMINARY RESULTS FROM PLGG TASKFORCE.MB-59IMAGING OF METASTATIC MEDULLOBLASTOMA IN THE MOLECULAR ERA.MB-80OUTCOME OF CHILDREN WITH POSTERIOR FOSSA MEDULLOBLASTOMA.Differential patterns of metastatic dissemination across medulloblastoma subgroups.Can telomerase activity be unleashed to refine prognosis within ependymoma subgroups?Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System.Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology.Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience.Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma.Long-term visual outcomes of craniopharyngioma in children.A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia.MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center StudyRare IDH1 variants are common in pediatric hemispheric diffuse astrocytomas and frequently associated with Li-Fraumeni syndrome
P50
Q37659087-FF79DE18-2899-46D0-B00D-B74F7F1B2886Q38670000-E7DABF4B-9929-4112-988A-72AC06953AC3Q38670250-68898C60-79EA-43EA-8BF1-73155F2B9048Q38671456-9696B196-0F02-48F6-8C50-BE80FD998F98Q38962177-C1A818B8-3C13-4C58-9A5C-82F289F25563Q39409604-93063891-A12A-447B-8E97-81922A5804BAQ39931639-FD942809-A1C4-4C34-9963-59631ACAD884Q40117605-F08C1D20-6A81-4E60-859F-475193777418Q40121818-CA91267B-5892-472B-9DD3-AC6C2116EFF9Q42783856-6C1FADDF-6CD7-43FF-93D9-8B1B07BC2F3CQ46347861-5350FD69-22F1-444D-8BC4-C33ECF6B960CQ46348552-101D6179-60B2-49D0-B092-6B93DB61BDCDQ46351832-AF22F6F9-FE00-4E6B-B774-5A72B7A8030CQ46353389-68A05B93-27F3-4048-8DDE-55BD0099110BQ46353493-9D1776AA-A991-4A5B-8D33-280B5E422ABDQ46353593-4B815136-B646-4DE2-BEA5-F2885B6D9241Q46353764-4EB2691E-D75D-4239-8A7B-3A63510B90EFQ46355003-1368FDE1-89F1-4E6C-9520-7A38843ABFCFQ46355332-AFD89400-C132-4F31-B03C-B80FB9E058E8Q47197600-4E4848C0-0240-4522-856D-C9FC85A9E93AQ47719269-7DB3422C-50C0-4574-99FD-9E948C9C0012Q47869458-CE5B05CC-CC40-49E5-8157-83EB617B23D0Q48011531-E5C61A75-9A71-4F22-8BFA-C568AE7095ADQ48167111-3778FF23-170E-4D83-A2D7-477DE81BEAC2Q48630455-69729D42-B2BB-472B-BE05-2FFC4D2D27FBQ49980165-7DFF1915-65C1-4F19-B2E5-5B801BF3CDEBQ50422142-46238273-0A16-4DB0-8C74-9A5F88061E3AQ54393948-6EA950B2-E3BF-4ADD-B2C7-785CB7FD4409Q60595474-C05F4DDA-C929-41A8-BA26-7765F8FA5843Q92385759-113418CD-D127-4C04-A2AB-95543E70E6A1
P50
description
dětský onkolog
@cs
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Michal Zapotocky
@ast
Michal Zapotocky
@en
Michal Zapotocky
@es
Michal Zapotocky
@nl
Michal Zápotocký
@cs
type
label
Michal Zapotocky
@ast
Michal Zapotocky
@en
Michal Zapotocky
@es
Michal Zapotocky
@nl
Michal Zápotocký
@cs
prefLabel
Michal Zapotocky
@ast
Michal Zapotocky
@en
Michal Zapotocky
@es
Michal Zapotocky
@nl
Michal Zápotocký
@cs
P214
P21
P214
P31
P496
0000-0002-9013-2546